China's innovative pharmaceutical companies face new challenges in expanding overseas marketsIn recent years, China's innovative pharmaceutical companies have made significant progress in R&D capabilities and international layout, but with the intensification of global market competition and changes

Yaotang Biotech completed more than 300 million yuan in round B financing, focusing on gene editing therapyRecently, the field of gene editing has received major news - Yaotang Biotech announced that it had completed a Series B financing of more than 300 million yuan, led by a number of well-known i

Dual AAV gene therapy strategy brings new hope to patients with Usher type 1B retinopathyIn recent years, significant progress has been made in the field of gene therapy, especially in the treatment of rare hereditary diseases. Recently, a study on dual-AAV gene therapy strategies has brought new ho

Competition in the global health industry is becoming increasingly fierceIn recent years, the global health industry has shown a rapid development trend, especially in the post-epidemic era, countries have increased their investment in the field of medical and health, and technological innovation an

The oral beauty market is expected to reach 65 million users in 2025, and the market size exceeds 25.57 billion.In recent years, the oral beauty market has risen rapidly and has become an important part of the beauty and health industry. As consumers' recognition of the beauty concept of "both inter

Cambrian's revenue surged by 4347.82% year-on-year in the first half of the year, and the AI ​​chip track explodedRecently, Cambrian (688256.SH) released its first half of 2023 financial report. Data showed that its revenue surged by 4347.82% year-on-year, becoming the most dazzling "dark horse"

Encourage traditional Chinese medicine service export bases and international medical insurance institutions to strengthen cooperationIn recent years, the influence of traditional Chinese medicine on a global scale has been increasing, and more and more countries and regions have begun to recognize

Darui Bio's new GalNAc-siRNA drug RN3161 targeted to INHBE was accepted in Australia's clinical trial application, aiming to lose fat while maintaining weight lossRecently, Darui Bio announced that its new GalNAc-siRNA drug RN3161 developed by it has been accepted in Australia's clinical trial appli

REGENXBIO gene therapy RGX-121 is used to treat type II mucopolysaccharide storage disorder (MPS II) published positive clinical dataRecently, biotechnology company REGENXBIO released positive clinical data on its gene therapy RGX-121 for the treatment of type II mucopolysaccharide storage disorder

The 2025 China Rare Disease Summit Forum will be held in Wuhan from September 19 to 21Recently, the preparations for the 2025 China Rare Disease Summit Forum were officially launched. This highly anticipated industry event is scheduled to be held at the Wuhan International Expo Center from September